TX-FLUENCE
7.4.2022 15:02:07 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, released results from its intercanopy lighting research in collaboration with Wageningen University & Research (WUR). Fluence’s research showed that intercanopy lighting treatments at a high intensity combined with top light increased yield in Hi Power and Skyson cucumber cultivars as well as Merlice and Brioso tomato cultivars.
Following Fluence’s multiyear research on the overall effects of broad-spectrum lighting solutions on plant development, Fluence and WUR further investigated the effects of various light distributions and intensities on plant morphology and fruit quality throughout a winter season.
“Growers have used the same benchmarks for vine crop lighting strategies for decades. Those benchmarks were typically derived from crops grown under high-pressure sodium fixtures that limited potential light intensity due to excess heat,” said David Hawley, principal scientist for Fluence. “LEDs virtually eliminate that restriction. As Fluence seeks to explore how to empower growers to be as productive as possible by maximizing their bottom lines, we wanted to investigate not only how higher intensities affect crops, but how crops use energy within the canopy. Our research overwhelmingly showed that intercanopy lighting in tandem with a top light strategy at a higher intensity boosted yields over conventional lighting strategies.”
Fluence and WUR studied cucumbers and tomatoes in the Netherlands under four light treatments: top light only at 250 µmol/m-2 /s-1 , top light and intercanopy lighting at 250 µmol/m-2 /s-1 , top light only at 375 µmol/m-2 /s-1 , and top light and intercanopy lighting at 375 µmol/m-2 /s-1 . Under the treatments with both top light and intercanopy lighting, two-thirds of the total PPFD were applied to the top of the canopy with Fluence’s VYPR luminaire, with the other third applied through Fluence’s VYNE intercanopy light.
Key findings from the studies include:
- Adding intercanopy lighting at the higher total intensity increased cumulative yield in both cucumber cultivars up to 110% compared to the top light-only treatment at the lower intensity.
- Similarly, adding intercanopy lighting at the higher total intensity enabled a less aggressive pruning strategy that, in combination with the higher light intensity, also increased the cumulative number of cucumber fruits in both cultivars up to 53% compared to the top light-only treatment at the lower intensity.
- Both cucumber cultivars also saw a decrease in total plant height and more compact morphology at the higher intensity treatments.
- Adding intercanopy lighting at the higher total intensity also increased cumulative yield and the total number of fruits up to 62% and 57%, respectively, in both tomato cultivars over the top light-only treatment at the lower intensity.
To ensure high-quality crops year-round, cucumber and tomato greenhouse growers often explore supplemental lighting strategies to adequately light plants during darker fall and winter months. With Fluence and WUR’s latest intercanopy lighting research, growers can now consider additional light distribution options to optimize yield and quality to meet their cultivation goals.
For more information on Fluence and its ongoing research initiatives, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
